南微醫學(688029.SH):2024年淨利潤5.5億元 同比增長13.53%
格隆匯2月24日丨南微醫學(688029.SH)公佈2024年度業績快報,2024年度,公司實現營業總收入276,051.06萬元,較上年同期增長14.47%;歸屬於母公司所有者的淨利潤55,166.57萬元,較上年同期增長13.53%;歸屬於母公司所有者的扣除非經常性損益的淨利潤54,286.65萬元,較上年同期增長17.21%。報吿期末,公司財務狀況良好,總資產475,936.77萬元,較報吿期初增長8.35%;歸屬於母公司的所有者權益383,102.50萬元,較報吿期初增長6.07%。
面對國內外錯綜複雜的局勢,公司勇於迎接挑戰,堅持自主研發、醫工創新和產學研合作,國內營銷不斷深化市場,海外渠道覆蓋面進一步擴大,生產運營方式不斷優化和轉型,保持了穩定持續發展的良好態勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.